Boxer Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Boxer Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-600,000	Closed	-$23.6M	–	61
2024 Q3	$23.6M	Hold	600,000	–	–	1.16%	24
2024 Q2	$23.4M	Hold	600,000	–	–	1.23%	25
2024 Q1	$25.8M	Hold	600,000	–	–	1.28%	23
2023 Q4	$27.6M	Hold	600,000	–	–	1.38%	23
2023 Q3	$20.5M	Hold	600,000	–	–	1.09%	31
2023 Q2	$23.1M	Hold	600,000	–	–	1.07%	33
2023 Q1	$21.5M	Hold	600,000	–	–	1.05%	32
2022 Q4	$23.7M	Hold	600,000	–	–	1.25%	30
2022 Q3	$21.7M	Hold	600,000	–	–	1.22%	30
2022 Q2	$18.3M	Hold	600,000	–	–	1.16%	30
2022 Q1	$18.3M	Hold	600,000	–	–	0.94%	34
2021 Q4	$18.7M	Sell	600,000 -257,000	-30%	-$7.68M	0.73%	32
2021 Q3	$13.1M	Hold	857,000	–	–	0.46%	55
2021 Q2	$16M	Buy	+857,000	New	+$15.8M	0.56%	54
2020 Q4	–	Sell	-600,000	Closed	-$6.64M	–	86
2020 Q3	$6.64M	Hold	600,000	–	–	0.23%	62
2020 Q2	$7.52M	Hold	600,000	–	–	0.33%	50
2020 Q1	$6.8M	Buy	+600,000	New	+$8.54M	0.46%	46
2018 Q4	–	Sell	-300,000	Closed	-$3.96M	–	28
2018 Q3	$3.96M	Buy	+300,000	New	+$3.48M	0.44%	21

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Boxer Capital's XENE Position: Q4 2024 in Review

Boxer Capital sold out of Xenon Pharmaceuticals (XENE) in Q4 2024, closing a stake of 600,000 shares — an estimated $23.6M sold.

Boxer Capital first reported a position in XENE in Q3 2018 and held it in 18 quarters. The position peaked at $27.6M in Q4 2023. 209 funds tracked by Wall St. Rank hold XENE as of Q4 2024.

Boxer Capital reported no remaining Xenon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 600,000 Xenon Pharmaceuticals shares in Q4 2024, an estimated $23.6M.
Boxer Capital first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 18 quarters.
Boxer Capital's Xenon Pharmaceuticals position peaked at $27.6M in Q4 2023.
209 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.